<DOC>
	<DOC>NCT01471223</DOC>
	<brief_summary>The purpose of the study is to estimate the incidence rates of Post-transplant Lymphoproliferative Disorder (PTLD), malignancy and hospitalized infections in adult kidney-only transplant recipients treated with Belatacept, and compared the incidences to the incidences in those treated with Calcineurin inhibitor (CNI) based regimens at the time of transplantation.</brief_summary>
	<brief_title>Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study</brief_title>
	<detailed_description>Time Perspective: Prospective design, Retrospective data collection and analysis</detailed_description>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1st kidney only transplant during study, at one of the transplant centers participating in CTS, received Belatacept or a CNI at the time of transplantation Patients with a history of malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>